2/5/2014 Inaccurate Article Sends CytRx Shares Lower http://wallstcheatsheet.com/stocks/inaccurate-article-sends-cytrx-shares-lower.html/?ref=YF 1/6 SUBSCRIBER LOGIN Trending: 5 of America’s Favorite Automotive Brands (4:08 PM) Follow 22.3K f $0.01 Web Hosting www.hostgator.com/1Penny Get Your First Month for 1 Cent. Try Our AwardWinning Service Now! STOCK NEWS INVESTING IDEAS ECON & POLICY PERSONAL FINANCE TOOLS FOR INVESTORS Search Quotes o 35k Like HOME / EXPERT / Inaccurate Article Sends CytRx Shares Lower CytRx Corporation (NASDAQ:CYTR ) shares have surged higher since last week because of positive data from the company’s Phase 2b first-line soft tissue sarcoma trial. The company reported statistically significant results and demonstrated 80 to 100 percent TOM MEYER | MORE ARTICLES DECEMBER 18, 2013 Page 1 of 3 view all Advertisement Advertisement Trade with TradeStation Trad commissionfree for 90 days. More. Advertisement
6
Embed
Inaccurate Article Sends CytRx Shares Lower $0.01 Web Hostingmoxreports.com/wp-content/uploads/wscs_cytr_2013_12_18_TomMeyer.pdfprice after that issuance. It had long been expected
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Trending 5 of Americarsquos Favorite Automotive Brands (408
PM)
Follow 223K followers
$001 Web Hostingwwwhostgatorcom1Penny
Get Your First Month for 1 Cent Try Our AwardshyWinning Service Now
STOCK NEWS INVESTING IDEAS ECON amp POLICY PERSONAL FINANCE TOOLS FOR INVESTORS Search Quotes or News
35kLike
HOME EXPERT
Inaccurate Article Sends CytRx Shares Lower
CytRx Corporation (NASDAQCYTR) shares have surged highersince last week because of positive data from the companyrsquosPhase 2b first-line soft tissue sarcoma trial The company reportedstatistically significant results and demonstrated 80 to 100 percent
TOM MEYER | MORE ARTICLESDECEMBER 18 2013
Page 1 of 3view all
Advertisement
Advertisement
Trade with TradeStation shy Tradecommissionshyfree for 90 days More
superiority over doxorubicin in progression-free survival Theresults also showed that aldoxorubicin had a higher overallresponse rate than the current standard of care doxorubicin
Shares of CytRx traded as high as $679 last week before closingthe week at $572 a gain of roughly 150 percent from whereshares began on Monday December 9 Unfortunately aninaccurate report was published on Monday December 16 by TheStreetrsquos Adam Feuerstein The report contained severalinaccuracies which caused shares of CytRx to sell off by morethan 10 percent Mr Feuerstein raised three points that need to beaddressed
Option Grants before Aldoxorubicin Press ReleaseCompared CytRx data to that of Ziopharm Oncology (NASDAQZIOP)Geographic Distribution
The Streetrsquos article seemed to imply that CytRx managementpurposely issued option grants to insiders knowing that a pressrelease would cause the shares to spike shortly after That isinaccurate The CytRx board meets at least once per quarterAdditionally the company has demonstrated a history ofconducting board meetings in December and issuing option grantsduring those same December meetings
In fact just last year CytRx had a board meeting and optionissuance on December 10 and there was no dramatic spike inprice after that issuance It had long been expected that Phase 2bdata would be reported in December 2013 as per the companyrsquostimeline that has been kept up to date on the company websiteThere were also several articles written by various bloggers thatcontinued to mention that Phase 2b data would be reported nearyear-end If the option grants would have been given after theshares spiked with a low option strike there would have been asmuch if not more criticism Itrsquos also important to note that none ofthe board members have ever exercised their options That speaksto their long-term view on the stock and the significant marketpotential that aldoxorubicin has
The Death of the PCThe days of paying for costly software upgrades are numbered The PC will soon beobsolete And BusinessWeek reports 70 of Americans are already using thetechnology that will replace it Merrill Lynch calls it a $160 billion opportunityComputing giants including IBM Yahoo and Amazon are racing to be the first to cashin on this PCshykilling revolution Yet a small group of littleshyknown companies have a hugehead start Get the full details on these companies and the technology that is destroyingthe PC in a free video from The Motley Fool Enter your email address below to viewthis stunning video
The Motley Fool Terms And Conditions
Wall St Cheat Sheet Privacy Policy
More Articles About CytRx Corporation NASDAQCYTR
Threshold Pharmaceuticals ZIOPHARM Oncology
To contact the reporter on this storystaffwriterswallstcheatsheetcomTo contact the editor responsible for this storyeditorswallstcheatsheetcom
Wall St Cheat Sheet has been featured in these fine media outlets
Add a comment8 comments
singaporetiger (signed in using yahoo)The AF analysis is even worse than reported in this article (its apples tooranges comparison) In the Ziopharm Picasso III trial patients were excludedif they ever received an anthracycline (including Dox) in any adjuvant orneoadjuvant setting In the CYTR trial patients were allowed to have usedDox in the adjuvant and neoadjuvant setting meaning that some patients hadsurgery then Dox and the tumor grew back with mets These patients areunlikely to respond to Dox compared to patients that were truly naive to Doxsuch as in the Ziopharm Phase III Therefore one would expect a lower PFSand a lower clinical response rate in the CYTR study compared to theZiopharm phase III trial There is nothing inconsistent with the CYTR dataReply middot middot Like middot Follow Post middot December 18 2013 at 705am1
me (signed in using yahoo)Wow you just crushed Feuerstein Great job Hate that guyReply middot middot Like middot Follow Post middot December 18 2013 at 650am1
Nir Etkovitz middot תיכון אחד העםthank you for your interesting articleReply middot middot Like middot Follow Post middot December 18 2013 at 1105am1
backofthebusnj (signed in using yahoo)Feuerstein is Jimmy Crammers butt buddy They both lie to manipulate stockprices for their pals on wall streetReply middot Like middot Follow Post middot Edited middot December 19 2013 at 241pm
tomsilver200 (signed in using yahoo)Cytrx is in on-going discussions with big pharma about partnershiphellipReply middot Like middot Follow Post middot December 18 2013 at 440pm
superiority over doxorubicin in progression-free survival Theresults also showed that aldoxorubicin had a higher overallresponse rate than the current standard of care doxorubicin
Shares of CytRx traded as high as $679 last week before closingthe week at $572 a gain of roughly 150 percent from whereshares began on Monday December 9 Unfortunately aninaccurate report was published on Monday December 16 by TheStreetrsquos Adam Feuerstein The report contained severalinaccuracies which caused shares of CytRx to sell off by morethan 10 percent Mr Feuerstein raised three points that need to beaddressed
Option Grants before Aldoxorubicin Press ReleaseCompared CytRx data to that of Ziopharm Oncology (NASDAQZIOP)Geographic Distribution
The Streetrsquos article seemed to imply that CytRx managementpurposely issued option grants to insiders knowing that a pressrelease would cause the shares to spike shortly after That isinaccurate The CytRx board meets at least once per quarterAdditionally the company has demonstrated a history ofconducting board meetings in December and issuing option grantsduring those same December meetings
In fact just last year CytRx had a board meeting and optionissuance on December 10 and there was no dramatic spike inprice after that issuance It had long been expected that Phase 2bdata would be reported in December 2013 as per the companyrsquostimeline that has been kept up to date on the company websiteThere were also several articles written by various bloggers thatcontinued to mention that Phase 2b data would be reported nearyear-end If the option grants would have been given after theshares spiked with a low option strike there would have been asmuch if not more criticism Itrsquos also important to note that none ofthe board members have ever exercised their options That speaksto their long-term view on the stock and the significant marketpotential that aldoxorubicin has
The Death of the PCThe days of paying for costly software upgrades are numbered The PC will soon beobsolete And BusinessWeek reports 70 of Americans are already using thetechnology that will replace it Merrill Lynch calls it a $160 billion opportunityComputing giants including IBM Yahoo and Amazon are racing to be the first to cashin on this PCshykilling revolution Yet a small group of littleshyknown companies have a hugehead start Get the full details on these companies and the technology that is destroyingthe PC in a free video from The Motley Fool Enter your email address below to viewthis stunning video
The Motley Fool Terms And Conditions
Wall St Cheat Sheet Privacy Policy
More Articles About CytRx Corporation NASDAQCYTR
Threshold Pharmaceuticals ZIOPHARM Oncology
To contact the reporter on this storystaffwriterswallstcheatsheetcomTo contact the editor responsible for this storyeditorswallstcheatsheetcom
Wall St Cheat Sheet has been featured in these fine media outlets
Add a comment8 comments
singaporetiger (signed in using yahoo)The AF analysis is even worse than reported in this article (its apples tooranges comparison) In the Ziopharm Picasso III trial patients were excludedif they ever received an anthracycline (including Dox) in any adjuvant orneoadjuvant setting In the CYTR trial patients were allowed to have usedDox in the adjuvant and neoadjuvant setting meaning that some patients hadsurgery then Dox and the tumor grew back with mets These patients areunlikely to respond to Dox compared to patients that were truly naive to Doxsuch as in the Ziopharm Phase III Therefore one would expect a lower PFSand a lower clinical response rate in the CYTR study compared to theZiopharm phase III trial There is nothing inconsistent with the CYTR dataReply middot middot Like middot Follow Post middot December 18 2013 at 705am1
me (signed in using yahoo)Wow you just crushed Feuerstein Great job Hate that guyReply middot middot Like middot Follow Post middot December 18 2013 at 650am1
Nir Etkovitz middot תיכון אחד העםthank you for your interesting articleReply middot middot Like middot Follow Post middot December 18 2013 at 1105am1
backofthebusnj (signed in using yahoo)Feuerstein is Jimmy Crammers butt buddy They both lie to manipulate stockprices for their pals on wall streetReply middot Like middot Follow Post middot Edited middot December 19 2013 at 241pm
tomsilver200 (signed in using yahoo)Cytrx is in on-going discussions with big pharma about partnershiphellipReply middot Like middot Follow Post middot December 18 2013 at 440pm
The Death of the PCThe days of paying for costly software upgrades are numbered The PC will soon beobsolete And BusinessWeek reports 70 of Americans are already using thetechnology that will replace it Merrill Lynch calls it a $160 billion opportunityComputing giants including IBM Yahoo and Amazon are racing to be the first to cashin on this PCshykilling revolution Yet a small group of littleshyknown companies have a hugehead start Get the full details on these companies and the technology that is destroyingthe PC in a free video from The Motley Fool Enter your email address below to viewthis stunning video
The Motley Fool Terms And Conditions
Wall St Cheat Sheet Privacy Policy
More Articles About CytRx Corporation NASDAQCYTR
Threshold Pharmaceuticals ZIOPHARM Oncology
To contact the reporter on this storystaffwriterswallstcheatsheetcomTo contact the editor responsible for this storyeditorswallstcheatsheetcom
Wall St Cheat Sheet has been featured in these fine media outlets
Add a comment8 comments
singaporetiger (signed in using yahoo)The AF analysis is even worse than reported in this article (its apples tooranges comparison) In the Ziopharm Picasso III trial patients were excludedif they ever received an anthracycline (including Dox) in any adjuvant orneoadjuvant setting In the CYTR trial patients were allowed to have usedDox in the adjuvant and neoadjuvant setting meaning that some patients hadsurgery then Dox and the tumor grew back with mets These patients areunlikely to respond to Dox compared to patients that were truly naive to Doxsuch as in the Ziopharm Phase III Therefore one would expect a lower PFSand a lower clinical response rate in the CYTR study compared to theZiopharm phase III trial There is nothing inconsistent with the CYTR dataReply middot middot Like middot Follow Post middot December 18 2013 at 705am1
me (signed in using yahoo)Wow you just crushed Feuerstein Great job Hate that guyReply middot middot Like middot Follow Post middot December 18 2013 at 650am1
Nir Etkovitz middot תיכון אחד העםthank you for your interesting articleReply middot middot Like middot Follow Post middot December 18 2013 at 1105am1
backofthebusnj (signed in using yahoo)Feuerstein is Jimmy Crammers butt buddy They both lie to manipulate stockprices for their pals on wall streetReply middot Like middot Follow Post middot Edited middot December 19 2013 at 241pm
tomsilver200 (signed in using yahoo)Cytrx is in on-going discussions with big pharma about partnershiphellipReply middot Like middot Follow Post middot December 18 2013 at 440pm
The Death of the PCThe days of paying for costly software upgrades are numbered The PC will soon beobsolete And BusinessWeek reports 70 of Americans are already using thetechnology that will replace it Merrill Lynch calls it a $160 billion opportunityComputing giants including IBM Yahoo and Amazon are racing to be the first to cashin on this PCshykilling revolution Yet a small group of littleshyknown companies have a hugehead start Get the full details on these companies and the technology that is destroyingthe PC in a free video from The Motley Fool Enter your email address below to viewthis stunning video
The Motley Fool Terms And Conditions
Wall St Cheat Sheet Privacy Policy
More Articles About CytRx Corporation NASDAQCYTR
Threshold Pharmaceuticals ZIOPHARM Oncology
To contact the reporter on this storystaffwriterswallstcheatsheetcomTo contact the editor responsible for this storyeditorswallstcheatsheetcom
Wall St Cheat Sheet has been featured in these fine media outlets
Add a comment8 comments
singaporetiger (signed in using yahoo)The AF analysis is even worse than reported in this article (its apples tooranges comparison) In the Ziopharm Picasso III trial patients were excludedif they ever received an anthracycline (including Dox) in any adjuvant orneoadjuvant setting In the CYTR trial patients were allowed to have usedDox in the adjuvant and neoadjuvant setting meaning that some patients hadsurgery then Dox and the tumor grew back with mets These patients areunlikely to respond to Dox compared to patients that were truly naive to Doxsuch as in the Ziopharm Phase III Therefore one would expect a lower PFSand a lower clinical response rate in the CYTR study compared to theZiopharm phase III trial There is nothing inconsistent with the CYTR dataReply middot middot Like middot Follow Post middot December 18 2013 at 705am1
me (signed in using yahoo)Wow you just crushed Feuerstein Great job Hate that guyReply middot middot Like middot Follow Post middot December 18 2013 at 650am1
Nir Etkovitz middot תיכון אחד העםthank you for your interesting articleReply middot middot Like middot Follow Post middot December 18 2013 at 1105am1
backofthebusnj (signed in using yahoo)Feuerstein is Jimmy Crammers butt buddy They both lie to manipulate stockprices for their pals on wall streetReply middot Like middot Follow Post middot Edited middot December 19 2013 at 241pm
tomsilver200 (signed in using yahoo)Cytrx is in on-going discussions with big pharma about partnershiphellipReply middot Like middot Follow Post middot December 18 2013 at 440pm
Wall St Cheat Sheet has been featured in these fine media outlets
Add a comment8 comments
singaporetiger (signed in using yahoo)The AF analysis is even worse than reported in this article (its apples tooranges comparison) In the Ziopharm Picasso III trial patients were excludedif they ever received an anthracycline (including Dox) in any adjuvant orneoadjuvant setting In the CYTR trial patients were allowed to have usedDox in the adjuvant and neoadjuvant setting meaning that some patients hadsurgery then Dox and the tumor grew back with mets These patients areunlikely to respond to Dox compared to patients that were truly naive to Doxsuch as in the Ziopharm Phase III Therefore one would expect a lower PFSand a lower clinical response rate in the CYTR study compared to theZiopharm phase III trial There is nothing inconsistent with the CYTR dataReply middot middot Like middot Follow Post middot December 18 2013 at 705am1
me (signed in using yahoo)Wow you just crushed Feuerstein Great job Hate that guyReply middot middot Like middot Follow Post middot December 18 2013 at 650am1
Nir Etkovitz middot תיכון אחד העםthank you for your interesting articleReply middot middot Like middot Follow Post middot December 18 2013 at 1105am1
backofthebusnj (signed in using yahoo)Feuerstein is Jimmy Crammers butt buddy They both lie to manipulate stockprices for their pals on wall streetReply middot Like middot Follow Post middot Edited middot December 19 2013 at 241pm
tomsilver200 (signed in using yahoo)Cytrx is in on-going discussions with big pharma about partnershiphellipReply middot Like middot Follow Post middot December 18 2013 at 440pm